Ladenburg Thalmann upgraded shares of Myriad Genetics (NASDAQ:MYGN) from a neutral rating to a buy rating in a report issued on Tuesday, TheFlyOnTheWall.com reports. They currently have $28.00 target price on the stock.
A number of other firms have also recently commented on MYGN. Analysts at Ned Davis Research downgraded shares of Myriad Genetics (NASDAQ:MYGN) from a buy rating to a neutral rating in a research note to investors on Monday. Separately, analysts at Zacks reiterated a neutral rating on shares of Myriad Genetics (NASDAQ:MYGN) in a research note to investors on Thursday, September 19th. They now have a $27.00 price target on the stock. Finally, analysts at Zacks reiterated a neutral rating on shares of Myriad Genetics (NASDAQ:MYGN) in a research note to investors on Friday, August 16th. They now have a $29.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $34.00.
Myriad Genetics (NASDAQ:MYGN) traded up 0.77% on Tuesday, hitting $24.95. The stock had a trading volume of 418,588 shares. Myriad Genetics has a one year low of $22.61 and a one year high of $38.27. The stock’s 50-day moving average is $26.56 and its 200-day moving average is $28.42. The company has a market cap of $2.007 billion and a P/E ratio of 13.99. Myriad Genetics also was the recipient of some unusual options trading on Monday. Stock investors acquired 11,342 put options on the company. This represents an increase of approximately 365% compared to the average daily volume of 2,438 put options.
Myriad Genetics (NASDAQ:MYGN) last released its earnings data on Tuesday, August 13th. The company reported $0.53 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.44 by $0.09. The company had revenue of $174.10 million for the quarter, compared to the consensus estimate of $159.87 million. During the same quarter in the prior year, the company posted $0.34 earnings per share. The company’s quarterly revenue was up 30.9% on a year-over-year basis. Analysts expect that Myriad Genetics will post $1.91 EPS for the current fiscal year.
Myriad Genetics, Inc (NASDAQ:MYGN) is a molecular diagnostic company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.